...
首页> 外文期刊>Clinical Rheumatology >Supernatants from culture of type I collagen-stimulated PBMC from patients with cutaneous systemic sclerosis versus localized scleroderma demonstrate suppression of MMP-1 by fibroblasts
【24h】

Supernatants from culture of type I collagen-stimulated PBMC from patients with cutaneous systemic sclerosis versus localized scleroderma demonstrate suppression of MMP-1 by fibroblasts

机译:皮肤系统性硬化症与局限性硬皮病患者的I型胶原蛋白刺激的PBMC培养上清液显示成纤维细胞抑制了MMP-1

获取原文
获取原文并翻译 | 示例
           

摘要

Systemic sclerosis (SSc) is a chronic fibrosing disease characterized by vasculopathy, autoimmunity, and an accumulation of collagen in tissues. Numerous studies have shown that compared to healthy or diseased controls, the peripheral blood mononuclear cells (PBMC) from patients with SSc produce a variety of cytokines or proliferate when cultured with solubilized type I collagen (CI) or constituent α1(II) and α2(I) polypeptide chains. The purpose of this study was to determine whether PBMC isolated from patients with SSc and cultured in vitro with soluble CI elaborated soluble mediators that inhibit the production of collagenase (i.e., matrix metalloproteinase, MMP-1) by fibroblasts. Supernatants of CI-stimulated PBMC from juvenile and adult diffuse cutaneous (dc)SSc patients significantly reduced MMP-1 production by SSc dermal fibroblasts, while supernatants of CI-stimulated PBMC from patients with localized scleroderma (LS) did not. CI-stimulated PBMC culture supernatants from patients with dcSSc in contrast to patients with LS exhibited increased levels of platelet-derived growth factor (PDGF)-AA, PDGF-BB, TNF-α, IL-13, and EGF. Prolonged culture of SSc dermal fibroblasts with recombinant PDGF-BB or IL-13 inhibited the induction of MMP-1 in response to subsequent TNF-α stimulation. These data suggest that therapies aimed at reducing these cytokines may decrease collagen accumulation in SSc, preventing the development of chronic fibrosis.
机译:系统性硬化症(SSc)是一种慢性纤维化疾病,其特征在于血管病变,自身免疫和胶原在组织中的积累。大量研究表明,与健康或患病对照相比,SSc患者的外周血单核细胞(PBMC)与可溶性I型胶原(CI)或成分α1(II)和α2()一起培养时会产生多种细胞因子或增殖。 I)多肽链。这项研究的目的是确定PBMC是否从患有SSc的患者中分离出来,并在体外用可溶性CI精心制作,以抑制成纤维细胞产生胶原酶(即基质金属蛋白酶,MMP-1)的可溶性介体。来自青少年和成人弥漫性皮肤(dc)SSc患者的CI刺激的PBMC的上清液显着降低了SSc皮肤成纤维细胞产生的MMP-1产生,而来自局部硬皮病(LS)患者的CI刺激的PBMC的上清液却没有。与LS患者相反,CI刺激的dcSSc患者的PBMC培养上清液的血小板衍生生长因子(PDGF)-AA,PDGF-BB,TNF-α,IL-13和EGF水平升高。用重组PDGF-BB或IL-13长时间培养SSc真皮成纤维细胞会抑制MMP-1的诱导,从而响应随后的TNF-α刺激。这些数据表明,旨在减少这些细胞因子的疗法可能会减少SSc中的胶原蛋白积聚,从而阻止慢性纤维化的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号